14
Nov
2019

Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Pfizer, BioNTech Vaccine Shows Life, but Cases Surge, Testing Falters & Prices Haunt
The Exponential Curves Re-Emerge
Merck Wins 2 Big Approvals, a Surprise from Old ‘Dex,’ and a Digital Therapeutics First
Inconvenient Truths and Rays of Light